Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 2/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.34 |
| ▸ | MYC | P01106 | 2/20 | 0.34 |
| ▸ | WDR5 | P61964 | 2/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.33 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.33 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3837191 | 1.00 | CXCR1 (0.36) | CXCR1CXCR2OPRK1ALDH1A1USP2 | |
| SCHEMBL1266937 | 1.00 | CXCR1 (0.36) | CXCR1CXCR2OPRK1ALDH1A1USP2 | |
| SCHEMBL1265512 | 0.94 | PDE7A (0.35) | CXCR1CXCR2ALDH1A1USP2MAPT | |
| SCHEMBL1267409 | 0.94 | PDE7A (0.35) | CXCR1CXCR2ALDH1A1USP2MAPT | |
| SCHEMBL1266794 | 0.94 | ALDH1A1 (0.37) | CXCR1CXCR2ALDH1A1USP2MAPT | |
| SCHEMBL1267284 | 0.94 | ADORA2B (0.35) | CXCR2OPRK1ALDH1A1USP2MAPT | |
| SCHEMBL1265999 | 0.91 | BTK (0.35) | ALDH1A1USP2MAPTKCNJ6KCNJ5 | |
| SCHEMBL1266466 | 0.91 | BTK (0.35) | ALDH1A1USP2MAPTKCNJ6KCNJ5 | |
| SCHEMBL3830940 | 0.91 | ALDH1A1 (0.37) | ALDH1A1USP2MAPTLMNA | |
| SCHEMBL1266952 | 0.90 | MET (0.39) | ALDH1A1USP2MAPTKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521460-B2 | Thienopyridone derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2009-04-21 | — | — | US | claimed |
| US-20070099894-A1 | e.g. 3-[(2,4-Difluorophenyl)amino]-2-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one; autoimmune, neurodegenerative disorders, antiinflammatory agent; p38 MAP kinase inhibitor | CELLTECH R&D LIMITED (GB) | 2007-05-03 | — | — | US | claimed |
| US-20110034495-A1 | Method of Modulating Stress-Activated Protein Kinase System | INTERMUNE, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-7521460-B2 | Thienopyridone derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2009-04-21 | — | — | US | disclosed |
| US-7482452-B2 | Process for preparing 3-aminothienopyridone derivatives | CELLTECH R&D LIMITED (GB) | 2009-01-27 | — | — | US | disclosed |
| EP-1638980-B1 | PROCESS FOR PREPARING 3-AMINOTHIENOPYRIDONE DERIVATIVES | UCB PHARMA SA (BE) | 2008-11-05 | — | — | EP | disclosed |
| US-20070191608-A1 | Process for preparing 3-aminothienopyridone derivatives | CELLTECH R&D LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| US-20070099894-A1 | e.g. 3-[(2,4-Difluorophenyl)amino]-2-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one; autoimmune, neurodegenerative disorders, antiinflammatory agent; p38 MAP kinase inhibitor | CELLTECH R&D LIMITED (GB) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191608-A1 | Process for preparing 3-aminothienopyridone derivatives | MAPK3, MAP3K6, MAP4K1 | CXCR1 3510/4885CXCR2 2574/4885OPRK1 1305/4885 |
| US-20110034495-A1 | Method of Modulating Stress-Activated Protein Kinase System | MAPKAPK2, MAP3K6, MAP3K2 | CXCR1 1737/4885CXCR2 1014/4885OPRK1 719/4885 |
| US-20070099894-A1 | e.g. 3-[(2,4-Difluorophenyl)amino]-2-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one; autoimmune, neurodegenerative disorders, antiinflammatory agent; p38 MAP kinase inhibitor | MAPK1, MAPKAPK2, MAPK6 | CXCR1 1291/4885CXCR2 947/4885OPRK1 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.